132 related articles for article (PubMed ID: 25605819)
1. Phase II study of PX-866 in recurrent glioblastoma.
Pitz MW; Eisenhauer EA; MacNeil MV; Thiessen B; Easaw JC; Macdonald DR; Eisenstat DD; Kakumanu AS; Salim M; Chalchal H; Squire J; Tsao MS; Kamel-Reid S; Banerji S; Tu D; Powers J; Hausman DF; Mason WP
Neuro Oncol; 2015 Sep; 17(9):1270-4. PubMed ID: 25605819
[TBL] [Abstract][Full Text] [Related]
2. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Koul D; Shen R; Kim YW; Kondo Y; Lu Y; Bankson J; Ronen SM; Kirkpatrick DL; Powis G; Yung WK
Neuro Oncol; 2010 Jun; 12(6):559-69. PubMed ID: 20156803
[TBL] [Abstract][Full Text] [Related]
3. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Gerstner ER; Ye X; Desideri S; Duda DG; Peereboom D; Lesser GJ; Chowdhary S; Wen PY; Grossman S; Supko JG
Neuro Oncol; 2017 Apr; 19(4):567-575. PubMed ID: 27663390
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma.
Boudreau CE; Najem H; Ott M; Horbinski C; Fang D; DeRay CM; Levine JM; Curran MA; Heimberger AB
Clin Cancer Res; 2021 Oct; 27(20):5528-5535. PubMed ID: 34433652
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Lassman AB; Pugh SL; Gilbert MR; Aldape KD; Geinoz S; Beumer JH; Christner SM; Komaki R; DeAngelis LM; Gaur R; Youssef E; Wagner H; Won M; Mehta MP
Neuro Oncol; 2015 Jul; 17(7):992-8. PubMed ID: 25758746
[TBL] [Abstract][Full Text] [Related]
6. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET; Lok E; Swanson KD
Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
[TBL] [Abstract][Full Text] [Related]
9. Numerical chromosomal instability mediates susceptibility to radiation treatment.
Bakhoum SF; Kabeche L; Wood MD; Laucius CD; Qu D; Laughney AM; Reynolds GE; Louie RJ; Phillips J; Chan DA; Zaki BI; Murnane JP; Petritsch C; Compton DA
Nat Commun; 2015 Jan; 6():5990. PubMed ID: 25606712
[TBL] [Abstract][Full Text] [Related]
10. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
[TBL] [Abstract][Full Text] [Related]
11. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Greenall SA; Donoghue JF; Van Sinderen M; Dubljevic V; Budiman S; Devlin M; Street I; Adams TE; Johns TG
Oncogene; 2015 Oct; 34(41):5277-87. PubMed ID: 25659577
[TBL] [Abstract][Full Text] [Related]
12. Letter: Reoperation for recurrent high-grade glioma: does tumor genetics play a role?
Zhao X; Bai HX; Zou Y; Yang L
Neurosurgery; 2015 Apr; 76(4):E496-7. PubMed ID: 25635893
[No Abstract] [Full Text] [Related]
13. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
[TBL] [Abstract][Full Text] [Related]
14. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Chowdhary SA; Ryken T; Newton HB
J Neurooncol; 2015 Apr; 122(2):367-82. PubMed ID: 25630625
[TBL] [Abstract][Full Text] [Related]
16. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.
Padfield E; Ellis HP; Kurian KM
Front Oncol; 2015; 5():5. PubMed ID: 25688333
[TBL] [Abstract][Full Text] [Related]
17. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.
Westphal M; Heese O; Steinbach JP; Schnell O; Schackert G; Mehdorn M; Schulz D; Simon M; Schlegel U; Senft C; Geletneky K; Braun C; Hartung JG; Reuter D; Metz MW; Bach F; Pietsch T
Eur J Cancer; 2015 Mar; 51(4):522-532. PubMed ID: 25616647
[TBL] [Abstract][Full Text] [Related]
18. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD; Becker KP; Mekhail T; Chowdhary SA; Eakle JF; Wright D; Langdon RM; Yost KJ; Padula GDA; West-Osterfield K; Scarberry M; Shaifer CA; Shastry M; Burris HA; Shih K
J Neurooncol; 2019 Sep; 144(2):303-311. PubMed ID: 31392595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
